Aim. To find out the relationship of the severity of patients condition, with acute myocardial infarction without ST segment elevation (NSTEMI), upon admission to the hospital on the basis of the Global Registry of Acute Coronary Events (GRACE) scale with the time interval between the onset of the disease and up to hospitalization (painhospitalization), and to clarify the effect of the GRACE score on the time interval to endovascular procedures (EVP) doorballoon, in real clinical practice. Material and methods. The study included 421 NSTEMI patients. Patients were admitted between 2000 and 2017. All patients underwent coronary angiography followed by EVP. Depending on the clinical condition, at admitted to the hospital, patients were divided into risk groups on the GRACE scale. According to the indicators painhospitalization and doorballoon 3 time intervals were allocated: 6 hours, 624 and 24 hours. Results. At admission, 73.9% (311) patients had an average and high risk on the GRACE scale. Patients with high risk were significantly more often (49.6%) hospitalized during the first 6 hours after onset of the disease than later (p0.05). 2/3 of all patients and 3/4 of patients with high risk had the time interval of painhospitalization up to 24 hours. 51.8% patients in the total group and 65.8% among high-risk patients had a doorballoon interval up to 6 hours. During first 24 hours after hospitalization EVP was successfully completed on 90.7% of patients. One patient had a fatal outcome. At discharge none of the patients were observed the symptoms of angina pectoris and congestive heart failure. Conclusion. In the all group, according to the allocated time intervals painhospitalization, patients were distributed practically equally. The severity of the condition of the studied patients is indicated by the fact that almost 3/4 of them had a high and average risk on the GRACE scale. It is encouraging that in the first 6 hours from the onset of the disease, high-risk patients were significantly more often hospitalized. Almost 2/3 of high-risk patients and more than half of all patients had a doorballoon indicator-up to 6 hours. It is important that in the first 24 hours, successful EVP was performed in 90.7% of patients. Thus, our results (low mortality, absence of angina and heart failure after EVP) indicate the correct management and treatment of NSTEMI patients, which is close to the latest world recommendations, comes from real life circumstances and can be recommended for real clinical practice.

No abstract

No abstract

No abstract

Aim. To evaluate the impact of antiplatelet agent clopidogrel on the aggregation platelet activity in patients with the history of the new coronavirus infection (COVID-19). Materials and methods. The impact of clopidogrel on platelet aggregation was studied in 47 patients with coronary heart disease after coronary artery stenting. The patients were assigned to 2 groups: group 1 comprised the patients who were not affected by COVID-19 (n=31), while group 2 comprised the patients who had COVID-19 (n=26) 3 months 1 year (mean, 51.3 months) before being included in the study. Results. The use of clopidogrel contributed to platelet aggregation decrease to the target levels in both groups. Platelet aggregation, assessed by Born technique, was 22.9 and 22.7% in groups 1 and 2, respectively. Platelet aggregation, assessed by the technique of optical transmission agregometry (system VerifyNow, P2Y12), was 152.3 and 147.2 PRU in groups 1 and 2, respectively. The data obtained in each group were not significantly different and attested to high laboratory effectiveness of clopidogrel. Besides, we did not find reliable differences in the levels of inflammation marker: C-reactive protein, fibrinogen, leucocytes, as well as of D-dimer, in the studied groups. Conclusion. In 3 months 1 year after COVID-19, the laboratory effectiveness of Clopidogrel used in standard dosage of 75 mg/day is compliant with target indices and does not differ from the effectiveness in patients with no history of COVID-19. At this stage of our study, the obtained results do not imply the necessity of changing the protocol of double antiplatelet therapy after coronary artery stenting in stable patients with coronary artery disease, who suffered COVID-19 three months 1 year before being included in the study, and show the necessity of further investigations.